Pharma-bio Serv,'s Revenue in the fiscal year 2025 $ 9.00 millions
Pharma-bio Serv,'s Revenue in the fiscal year 2024 $ 9.51 millions
Pharma-bio Serv,'s Revenue in the fiscal year 2023 $ 16.98 millions
Pharma-bio Serv,'s Revenue in the fiscal year 2022 $ 19.40 millions
Pharma-bio Serv,'s Revenue in the fiscal year 2020 $ 21.56 millions
PBSV Revenue third quarter 2027 Y/Y Growth Comment
Pharma-Bio Serv, Inc. achieved in the third quarter 2027, above Company average Revenue increase of 19.19% year on year, to $ 2.34 millions.
According to the results reported in the third quarter 2027, Pharma-bio Serv, Inc. achieved the best Revenue growth in Consulting Services industry. While Pharma-bio Serv, Inc.' s Revenue growth of 19.19% ranks overall at the positon no. 0 in the third quarter 2027.
Revenue by Quarter for the Fiscal Years 2024, 2025, 2026, 2027
Pharma-bio Serv,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
27.67 %
0.89 %
-33.85 %
(Apr 30 2011)
PBSV's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2027 Pharma-bio Serv, Inc. disclosed drop in Revenue from the second quarter by -13.48% to $ 2.34 millions, from $ 2.70 millions achived in the previous reporting period.
But that's not important problem, as Pharma-bio Serv,'s Revenue generally seem to plunge in this quarter.
Within Consulting Services industry Pharma-Bio Serv, Inc. achieved highest sequential Revenue growth. While Pharma-bio Serv,'s Revenue growth quarter on quarter, overall rank is 0.
In the III. Quarter 2027 Pharma-bio Serv, Inc. disclosed drop in Revenue from the second quarter by -13.48% to $ 2.34 millions, from $ 2.70 millions achived in the previous reporting period.
But that's not important problem, as Pharma-bio Serv,'s Revenue generally seem to plunge in this quarter.
Within Consulting Services industry Pharma-Bio Serv, Inc. achieved highest sequential Revenue growth. While Pharma-bio Serv,'s Revenue growth quarter on quarter, overall rank is 0.
Pharma-bio Serv,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jul 31 2026)
12 Months Ending (Apr 30 2026)
12 Months Ending (Jan 31 2026)
12 Months Ending (Oct 31 2025)
12 Months Ending (Jul 31 2025)
Cumulative Revenue 12 Months Ending
$ 9.48
$ 9.11
$ 8.82
$ 9.00
$ 9.18
Y / Y Revenue Growth (TTM)
3.26 %
-5.49 %
-8.08 %
-5.34 %
-14.75 %
Year on Year Revenue Growth Overall
Ranking
# 3667
# 2976
# 3370
# 3609
# 4359
Seqeuential Revenue Change (TTM)
4.09 %
3.24 %
-1.96 %
-2 %
-4.72 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 3667
# 2976
# 3370
# 3609
# 4359
Cumulative Revenue growth Comment
Pharma-bio Serv, saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 3.26% year on year, to $ 9 millions if the fiscal year would have ended in Jul 31 2026. Pharma-bio Serv,'s trailing twelve months Revenue growth was higher than company's average -1.66% and higher than -5.49% growth in Apr 30 2026. And, Pharma-bio Serv, realized the fastest Revenue growth, in Consulting Services industry. The momentum is even more impressive from twelve months ended Apr 30 2026 exhibited at 4.09 % increase from $9.11 millions in the period from Apr 30 2026 to Jul 31 2025.
Pharma-Bio Serv, Inc. achieved highest trailing twelve month year on year Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2976 to 3667.
Pharma-bio Serv, saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 3.26% year on year, to $ 9 millions if the fiscal year would have ended in Jul 31 2026. Pharma-bio Serv,'s trailing twelve months Revenue growth was higher than company's average -1.66% and higher than -5.49% growth in Apr 30 2026. And, Pharma-bio Serv, realized the fastest Revenue growth, in Consulting Services industry. The momentum is even more impressive from twelve months ended Apr 30 2026 exhibited at 4.09 % increase from $9.11 millions in the period from Apr 30 2026 to Jul 31 2025.
Pharma-Bio Serv, Inc. achieved highest trailing twelve month year on year Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2976 to 3667.
About Pharma-bio Serv, Revenue Growth Rates (PBSV), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
31.30%